Figure 1.
Forest plots of subgroup analyses of tislelizumab. A, Overall response rate. B, Complete response rate according to demographic and baseline disease characteristics. ASCT, autologous hematopoietic stem cell transplant; cHL, classical Hodgkin lymphoma; CI, confidence interval; CR, complete response; ECOG PS, Eastern Cooperative Oncology Group performance status; ORR, overall response rate.